MedCity News November 23, 2025
The Trump administration’s new deal lowers prices and expands access to GLP-1 drugs, but experts argue far broader reforms are needed to address high prescription drug costs overall.
When the Trump administration announced earlier this year that it would not finalize a provision proposed by the Biden administration to expand Medicare and Medicaid coverage of GLP-1s, many advocates responded with deep disappointment.
But this month, the Trump administration unveiled its own efforts to expand access to the popular weight loss drugs, announcing an agreement with GLP-1 manufacturers Eli Lilly and Novo Nordisk. The agreement will allow patients to access GLP-1s for significantly cheaper prices through TrumpRx, a government-run direct-to-consumer drug platform. It also reduces prices under Medicare and Medicaid, and...
Today's Sponsors
Today's Sponsor